Trevena (NASDAQ:TRVN) has been assigned a $5.00 price objective by analysts at Oppenheimer in a report issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective suggests a potential upside of 160.42% from the company’s current price.
Several other research analysts have also recently commented on the company. Zacks Investment Research cut Trevena from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research note on Saturday, January 20th. HC Wainwright boosted their price target on Trevena to $7.00 and gave the stock a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $7.06.
Trevena (NASDAQ:TRVN) traded down $0.06 during trading hours on Monday, hitting $1.92. The company had a trading volume of 840,797 shares, compared to its average volume of 777,382. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.71 and a current ratio of 3.71. Trevena has a fifty-two week low of $1.34 and a fifty-two week high of $3.98. The firm has a market capitalization of $119.62, a PE ratio of -1.57 and a beta of -0.61.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new stake in Trevena during the fourth quarter valued at approximately $130,000. Goldman Sachs Group Inc. raised its stake in Trevena by 343.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 195,253 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 151,257 shares in the last quarter. Virtu Financial LLC raised its stake in Trevena by 1,546.1% during the fourth quarter. Virtu Financial LLC now owns 191,701 shares of the biopharmaceutical company’s stock valued at $307,000 after buying an additional 180,055 shares in the last quarter. Bourgeon Capital Management LLC raised its stake in Trevena by 59.3% during the fourth quarter. Bourgeon Capital Management LLC now owns 137,800 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 51,300 shares in the last quarter. Finally, American Century Companies Inc. acquired a new stake in Trevena during the fourth quarter valued at approximately $135,000. Hedge funds and other institutional investors own 52.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/03/12/trevena-trvn-given-a-5-00-price-target-at-oppenheimer.html.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.